These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 15297406

  • 1. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK.
    Clin Cancer Res; 2004 Aug 01; 10(15):5048-57. PubMed ID: 15297406
    [Abstract] [Full Text] [Related]

  • 2. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E.
    Clin Cancer Res; 2005 May 15; 11(10):3854-61. PubMed ID: 15897586
    [Abstract] [Full Text] [Related]

  • 3. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
    Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, D'Aloisio S, Tolcher AW.
    Clin Cancer Res; 2001 Dec 15; 7(12):3920-7. PubMed ID: 11751483
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N, Scher HI.
    Clin Cancer Res; 2002 Mar 15; 8(3):679-83. PubMed ID: 11895895
    [Abstract] [Full Text] [Related]

  • 5. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
    Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, Patnaik A, Yeh IT, Izbicka E, Berg K, Tolcher AW.
    Ann Oncol; 2006 Feb 15; 17(2):313-21. PubMed ID: 16322117
    [Abstract] [Full Text] [Related]

  • 6. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.
    O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR.
    J Clin Oncol; 2005 Oct 20; 23(30):7697-702. PubMed ID: 16186597
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE.
    J Clin Oncol; 2004 Mar 15; 22(6):1110-7. PubMed ID: 15020613
    [Abstract] [Full Text] [Related]

  • 8. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, Hayes DF.
    Ann Oncol; 2004 Aug 15; 15(8):1274-83. PubMed ID: 15277270
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
    Galatin PS, Advani RH, Fisher GA, Francisco B, Julian T, Losa R, Sierra MI, Sikic BI.
    Invest New Drugs; 2011 Oct 15; 29(5):971-7. PubMed ID: 20349264
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.
    Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F, Collette L, Lacombe D, EORTC Genitourinary Tract Cancer Group.
    Ann Oncol; 2009 Jul 15; 20(7):1264-9. PubMed ID: 19297314
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
    Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB.
    Clin Cancer Res; 2004 Nov 15; 10(22):7662-70. PubMed ID: 15569999
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.
    Morris MJ, Cordon-Cardo C, Kelly WK, Slovin SF, Siedlecki K, Regan KP, DiPaola RS, Rafi M, Rosen N, Scher HI.
    Appl Immunohistochem Mol Morphol; 2005 Mar 15; 13(1):6-13. PubMed ID: 15722787
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Potential therapeutic applications of oblimersen in CLL.
    Koziner B.
    Oncology (Williston Park); 2004 Nov 15; 18(13 Suppl 10):32-8. PubMed ID: 15651175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.